Ibrutinib‐induced severe liver injury

Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B‐cell receptor pathway, is an effective therapeutic agent for B‐cell lymphomas. As these drugs are novel, long‐term or rare adverse events are not yet known. We report the first case of ibrutinib‐induced severe liver injury in a pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Nandikolla, Amara G., Derman, Olga, Nautsch, Deborah, Liu, Qiang, Massoumi, Hatef, Venugopal, Sangeetha, Braunschweig, Ira, Janakiram, Murali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458017/
https://www.ncbi.nlm.nih.gov/pubmed/28588800
http://dx.doi.org/10.1002/ccr3.881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458017/
https://www.ncbi.nlm.nih.gov/pubmed/28588800
http://dx.doi.org/10.1002/ccr3.881

Ejemplares similares